Xencor Stock News

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

Xencor (XNCR), Encore Wire (WIRE) & Silvergate Capital (SI) have been selected as the top profitable picks with a high net income ratio.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2021 Results - Earnings Call Transcript

Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Xencor press release (XNCR): Q4 GAAP EPS of $1.21 beats by $1.11.Revenue of $154.02M (+268.0% Y/Y) beats by $77.73M.The company expects to have cash to fund research and…

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights. “In 2021, we made significant decisions to advance our portfolio of internal XmAb® drug candidates — the initiation of Phase 2 trials

Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?